We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Diagnostic Tool Developed for Chronic Endometritis

By LabMedica International staff writers
Posted on 04 Apr 2018
Print article
Image: A histological micrograph showing endometrium with abundant plasma cells, which are diagnostic for chronic endometritis and scattered neutrophils (Photo courtesy of Nephron).
Image: A histological micrograph showing endometrium with abundant plasma cells, which are diagnostic for chronic endometritis and scattered neutrophils (Photo courtesy of Nephron).
Chronic endometritis is a persistent inflammation of the endometrial mucosa caused by bacterial pathogens. Although chronic endometritis can be asymptomatic, it is found in up to 40% of infertile patients and is responsible for repeated implantation failure and recurrent miscarriage.

Diagnosis of chronic endometritis is based on hysteroscopy of the uterine cavity, endometrial biopsy with plasma cells being identified histologically, while specific treatment is determined based on microbial culture. However, not all microorganisms implicated are easily or readily cultured needing a turnaround time of up to one week.

A team of international scientists working with those at Stanford University (Stanford, CA, USA) assessed endometrial samples from 113 patients assessed for chronic endometritis using at least one or several conventional diagnostic methods namely histology, hysteroscopy, and/or microbial culture. These samples were evaluated by reverse transcription polymerase chain reaction (RT-PCR) for the presence of nine chronic endometritis pathogens: Chlamydia trachomatis, Enterococcus, Escherichia coli, Gardnerella vaginalis, Klebsiella pneumoniae, Mycoplasma hominis, Neisseria gonorrhoeae, Staphylococcus, and Streptococcus. The sensitivity and specificity of the molecular analysis versus the classical diagnostic techniques were compared in the 65 patients assessed by all three-recognized classical methods.

The molecular method showed concordant results with histological diagnosis in 30 samples (14 double positive and 16 double negative) with a matching accuracy of 46.2%. Concordance of molecular and hysteroscopic diagnosis was observed in 38 samples (37 double positive and one double negative), with an accuracy of 58.5%. When the molecular method was compared to microbial culture, concordance was present in 37 samples (22 double positive and 15 double negative), a matching rate of 56.9%.

When cases of potential contamination and/or non-cultivable bacteria were considered, the accuracy increased to 66.2%. Of these 65 patients, only 27 patients had consistent histological plus hysteroscopic diagnosis revealing a 58.6% of non-concordant results. Only 13 out of 65 patients (20%) had consistent histology plus hysteroscopy plus microbial culture results. In these cases, the molecular microbiology matched in 10 cases showing a diagnostic accuracy of 76.9%. The molecular microbiology confirmed over half of the isolated pathogens and provided additional detection of non-culturable microorganisms.

In the endometrial samples with concordant histology plus hysteroscopy plus microbial culture results, the molecular microbiology diagnosis demonstrates 75% sensitivity, 100% specificity, 100% positive and 25% negative predictive values, 0% false positive and 25% false negative rates. The authors concluded that the molecular microbiology method is a fast, and inexpensive diagnostic tool that allows for the identification of culturable and non-culturable endometrial pathogens associated with chronic endometritis. The results obtained were similar to all three classical diagnostic methods together with a degree of concordance of 76.9% providing an opportunity to improve the clinical management of infertile patients with a risk of suffering from this ghost endometrial pathology. The study was published on February 22, 2018, in the American Journal of Obstetrics and Gynecology.

Related Links:
Stanford University

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.